| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
PROTAC Linkers; ADC Linkers.
|
|---|---|
| ln Vitro |
As a PROTAC and ADC linker, Fmoc-Gly-NH-CH2-O-CH2-Cbz itself has no intrinsic biological activity; it serves as a structural connector in the synthesis of bioconjugates. The Fmoc-protected glycine residue allows for solid-phase peptide synthesis (SPPS) elongation at the N-terminus, enabling the construction of longer peptide linkers. The Cbz-protected amine provides orthogonal protection that can be removed under different conditions (hydrogenolysis) than Fmoc (base-labile). The glycine residue provides a minimal, flexible amino acid spacer. The ether linkage introduces hydrophilicity. In ADC applications, this linker is part of the cleavable peptide linker of Deruxtecan, which is designed for cathepsin-mediated cleavage in the tumor microenvironment.
|
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final ADC or PROTAC conjugate after incorporation.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95-97%. The Fmoc group can be characterized by its characteristic UV absorption at 265 nm and 301 nm, and by its aromatic proton signals in NMR. The Cbz group can be characterized by its aromatic proton signals.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. In the synthesis of Deruxtecan, this building block is used in solid-phase peptide synthesis to assemble the GGFG peptide linker. The Fmoc group is removed with piperidine, and the next amino acid (glycine) is coupled. The Cbz group is removed by hydrogenolysis at the final stage. The complete Deruxtecan payload-linker complex is then conjugated to an antibody via a maleimide group. The resulting ADC is tested in cells for cytotoxicity and target-specific internalization.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For the final ADC conjugate, in vivo studies are conducted following institutional guidelines. The ADC is typically formulated in a suitable vehicle (e.g., PBS) and administered via intravenous (IV) injection to animal models (e.g., xenografts of HER2-expressing tumors). Efficacy is measured by tumor growth inhibition, and pharmacokinetics are assessed by measuring antibody and payload concentrations in plasma.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 474.51, a molecular formula of C27H26N2O6, and a standard purity of ≥95-97%. The IUPAC name is benzyl 1-(9H-fluoren-9-yl)-3,6-dioxo-2,9-dioxa-4,7-diazaundecan-11-oate. For storage, it should be kept long-term in a cool, dry place, sealed, away from moisture. It is soluble in DMSO and other organic solvents. The product should be protected from light. CAS: 1599440-07-9.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. It is not an approved therapeutic drug and has not been cleared for clinical use. It is a building block for the synthesis of research-grade ADC and PROTAC constructs.
|
| References |
[1]. NOGUCHI, Shigeru, et al. Method for selectively manufacturing antibody-drug conjugate. WO2017002776A1.
|
| Additional Infomation |
Fmoc-Gly-NH-CH2-O-CH2-Cbz is a key building block for the synthesis of Deruxtecan, the payload-linker complex of the clinically approved ADC Enhertu (trastuzumab deruxtecan). This ADC is used for the treatment of HER2-positive breast cancer and other HER2-expressing cancers. The GGFG tetrapeptide linker is a cathepsin-cleavable linker that is stable in circulation but rapidly cleaved inside lysosomes of target cancer cells, releasing the cytotoxic payload. The Fmoc and Cbz protecting groups enable orthogonal deprotection strategies for the controlled assembly of the linker and conjugation to the payload. This compound is also a valuable tool for the synthesis of PROTAC molecules that incorporate cleavable peptide linkers for tumor-targeted degradation.
|
| Molecular Formula |
C27H26N2O6
|
|---|---|
| Molecular Weight |
474.51
|
| Exact Mass |
474.505
|
| CAS # |
1599440-07-9
|
| PubChem CID |
118201358
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
733.0±60.0 °C at 760 mmHg
|
| Flash Point |
397.1±32.9 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.600
|
| LogP |
4.97
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
35
|
| Complexity |
688
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)COC(=O)COCNC(=O)CNC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
MZOSSDIBSRKPCO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H26N2O6/c30-25(29-18-33-17-26(31)34-15-19-8-2-1-3-9-19)14-28-27(32)35-16-24-22-12-6-4-10-20(22)21-11-5-7-13-23(21)24/h1-13,24H,14-18H2,(H,28,32)(H,29,30)
|
| Chemical Name |
benzyl 2-[[[2-(9H-fluoren-9-ylmethoxycarbonylamino)acetyl]amino]methoxy]acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1074 mL | 10.5372 mL | 21.0744 mL | |
| 5 mM | 0.4215 mL | 2.1074 mL | 4.2149 mL | |
| 10 mM | 0.2107 mL | 1.0537 mL | 2.1074 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
